Concurrent validity of different functional and neuroproteomic pain assessment methods in the rat osteoarthritis monosodium iodoacetate (MIA) model

Colombe Otis1,2, Julie Gervais1, Martin Guillot1,2, Julie-Anne Gervais1, Dominique Gauvin1,2, Catherine Péthel1,3, Simon Authier4, Marc-André Dansereau5, Philippe Sarret3, Johanne Martel-Pelletier6, Jean-Pierre Pelletier2, Francis Beaudry1,2 and Eric Troncy1,2*

Abstract

Background: Lack of validity in osteoarthritis pain models and assessment methods is suspected. Our goal was to 1) assess the repeatability and reproducibility of measurement and the influence of environment, and acclimatization, to different pain assessment outcomes in normal rats, and 2) test the concurrent validity of the most reliable methods in relation to the expression of different spinal neuropeptides in a chemical model of osteoarthritic pain.

Methods: Repeatability and inter-rater reliability of reflexive nociceptive mechanical thresholds, spontaneous static weight-bearing, treadmill, rotorod, and operant place escape/avoidance paradigm (PEAP) were assessed by the intraclass correlation coefficient (ICC). The most reliable acclimatization protocol was determined by comparing coefficients of variation. In a pilot comparative study, the sensitivity and responsiveness to treatment of the most reliable methods were tested in the monosodium iodoacetate (MIA) model over 21 days. Two MIA (2 mg) groups (including one lidocaine treatment group) and one sham group (0.9 % saline) received an intra-articular (50 μL) injection.

Results: No effect of environment (observer, inverted circadian cycle, or exercise) was observed; all tested methods except mechanical sensitivity (ICC <0.3), offered good repeatability (ICC ≥0.7). The most reliable acclimatization protocol included five assessments over two weeks. MIA-related osteoarthritic change in pain was demonstrated with static weight-bearing, punctate tactile allodynia evaluation, treadmill exercise and operant PEAP, the latter being the most responsive to analgesic intra-articular lidocaine. Substance P and calcitonin gene-related peptide were higher in MIA groups compared to naive (adjusted \( P = 0.016 \) or sham-treated (adj-\( P = 0.029 \)) rats. Repeated post-MIA lidocaine injection resulted in 34 times lower downregulation for spinal substance P compared to MIA alone (adj-\( P = 0.029 \)), with a concomitant increase of 17 % in time spent on the PEAP dark side (indicative of increased comfort).

(Continued on next page)
Background
Osteoarthritis (OA), the most common of all arthropathies in our aging population, is a leading cause of disability and represents a large (and growing) worldwide socio-economic cost [1]. It affects approximately 30 million adults in the USA [2], and this number is expected to double by 2020 [3], with longer life expectancy and the increasing incidence of obesity, two major risk factors for the disease. Despite critical importance in drug development, translation of OA therapies focusing either on structure (disease-modifying OA drugs) or pain (symptom-modifying OA drugs) from the bench to bedside has slowed [1, 4, 5]. Differences between preclinical OA models and the disease evaluated in clinical trials contribute to this failure. Rising criticism is noted over the classic translational research, which has failed to predict the efficacy of chronic pain treatments [6–9]. Most critics have targeted the poor validity and clinical relevance of experimental pain models using laboratory animals [10, 11]. It has also been hypothesized that current animal models are too reliant on evoked (reflexive) withdrawal responses and that development of meaningful assessment tools allowing, for instance, the measurement of continuous spontaneous pain, might help to translate experimental data to clinical practice [6, 12].

Naturally occurring OA models are recognized to present pathophysiological changes closest to clinical OA, particularly in large animals [13], but also entail experimental disadvantages (long period to onset, and variability of disease development). In contrast, chemical models cause the most rapidly progressing OA, requiring less invasive procedures and enabling standardization (with increased sample homogeneity). The monosodium iodoacetate (MIA) chemical OA model as described 25 years ago induces cartilage degeneration by disruption of chondrocyte metabolism (i.e., breaking down the cellular aerobic glycolysis). In rats, the MIA model is well-established and resembles the histological and pain-related characteristics of human degenerative OA [14–29]. Owing to the extensive description of the pain response in rats, the MIA OA model was proposed as a standard OA model for pain assessment [23, 30].

The quality of pain assessment methodologies is a cornerstone of preclinical studies targeting new analgesics [7, 10–12, 16, 31, 32]. Three different categories of pain expression can be evaluated in rats: reflexive measures, spontaneous measures, and operant responses [8, 31]. First, reflexive measures using stimulus-evoked responses are commonly used in rats to assess potential hyperalgesia and allodynia, recognized as a clinical expression of the neuropathic pain (nociceptive sensitization) component [8, 33–35]. These measures are generated by exposure to thermal, mechanical, or electrical stimulus, involving mainly spinal-level pain processing, and are also increasingly present in human quantitative sensory testing characterization of pain [36–38]. Second, spontaneous measures can be useful to quantify pain and/or wellbeing [8]. For example, kinetic (static or dynamic weight distribution) [14] or kinematic [39] (ambulation evaluation or characterization) measurement, and spontaneous activity [24] can indirectly assess quality of life in OA models. Pain-induced behaviors (scratching/licking/biting, hypophagia, vocalization, etc.) should also be considered in this category [37]. Finally, operant responses have been more recently introduced to characterize pain in animal models [8, 34, 40–44]. Operant testing is opposite to reflexive response testing as it allows the quantification of behavioral responses at higher levels of the brain, reproducing multiple dimensions of pain, including affective and cognitive changes and not only sensory-discriminative perception [42, 43, 45, 46]. This type of measure allows the observer to evaluate the aversive component of pain as operant tests give the animal an opportunity to avoid the painful condition [33, 40–43, 47–49].

In patients OA of the knee joint, pain is a combination of inflammatory, immune and neurogenic components participating in the hypersensitivity syndrome. Central sensitization mechanisms [50] include various biochemical processes such as increased spinal release of neurotransmitters and neuromodulators, and increased excitability of postsynaptic neurons. In an OA [51] and arthritis [52] rat model, higher levels of neuropeptides, such as substance P (SP) and calcitonin gene-related peptide (CGRP) have been found in the spinal cord. Thus, nervous system modulation seems to play a critical role in the development of the disease [53]. The contribution of these spinal neuromediators to neurogenic inflammation-mediated chronic pain in OA, and concomitant changes in

Conclusion: This study of normal rats and rats with pain established the most reliable and sensitive pain assessment methods and an optimized acclimatization protocol. Operant PEAP testing was more responsive to lidocaine analgesia than other tests used, while neuropeptide spinal concentration is an objective quantification method attractive to support and validate different centralized pain functional assessment methods.

Keywords: Animal preclinical model, Osteoarthritis, Monosodium iodoacetate, Methods, Validation, Acclimatization, Pain metrology, Neuropeptide
functional pain assessment methods has not been fully established.

With such a variety of methods for pain and analgesic response assessment, it is difficult to opt for the method(s) most adapted to specific conditions. The current study undertook to establish, the reliability of a panel of pain assessment methods (including reflexive, spontaneous, and operant testing) in normal rats, and the influence of environmental conditions, including acclimatization and experimental conditions of manipulation (observer, inverted circadian cycle, and exercise). The most reliable methods were then used to characterize OA pain in the well-established chemical MIA model in rats, while conducting concurrent validation of pain assessment methods in relation to the expression of different spinal neuropeptides and their responsiveness to treatment with intra-articular lidocaine.

**Methods**

**Ethics statement**

During the study, care and use of animals were subject to and approved by the Comité d’Éthique de l’Utilisation des Animaux de Université de Montréal (#Rech-1495) and conducted in accordance with principles outlined in the current Guide to the Care and Use of Experimental Animals published by the Canadian Council on Animal Care and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.

**Animals**

The present study was conducted on female (n = 63; excluding spares) Sprague-Dawley rats (Charles River Laboratories, Saint-Constant, QC, Canada) ranging from 225–300 g in weight at the beginning of experiment. The animals were housed under regular laboratory conditions and maintained under a light-dark cycle with food and water provided ad libitum. Body weight was obtained weekly. At the end of each experiment, the animals were returned to their housing colony.

**Phase 1: reliability of pain assessment methods in normal rats**

**Experimental design**

Phase 1 included a total of 39 normal rats distributed into 8 groups. First, the repeatability of measurements was tested for the influence of environment, including observer, inverted circadian cycle (activity during the day), and exercise (two groups of five animals in crossover). Additionally, repeatability over an extended period was tested again for static weight-bearing (SWB; one group of four animals also tested for exercise effect), and for tactile sensitivity and place escape/avoidance paradigm (PEAP) operant test (one group of five animals). Second, using the most reliable methods only, the influence of four acclimatization protocols (four groups of five animals) was tested to determine the most effective approach to obtain predictable data with low variability. Different pain assessment methods were selected to include reflexive, spontaneous behavior and operant measures.

**Influence of environment**

First, rats (n = 10) were randomly distributed into two groups of five. Animals were acclimated to the test apparatus on two occasions at day -3 and -1 before starting the experimentation. In a crossover design, the animals were subsequently assessed for three repeated days during light (1000–1400 h) and dark (2000–2400 h) cycles to test the influence of inverted circadian cycles. Both cycles were separated by a 3-day washout period without assessment. Dark cycle evaluations were performed under low-intensity red light. Animals were tested on each of six assessment days by two observers, with the following methods in this order of evaluation: mechanical and tactile sensitivity, SWB, treadmill exercise, mechanical and tactile sensitivity, SWB, PEAP operant test (without nociceptive stimulation) and rotarod acceptance. The mechanical and tactile nociceptive thresholds and SWB evaluation were performed before and after the treadmill exercise to verify the influence of exercise on these three pain assessment methods. Finally, PEAP and rotarod were performed at the end of the evaluation schedule to ensure respectively, that the length of the test, and possible falling from the test device would not impair the other outcomes. To test inter-rater reliability, two female observers were selected for their different levels of experience in laboratory animals (one intermediate, one with advanced expertise). Second, in complementary studies about test repeatability (after acclimatization on two occasions, at day -3 and -1), SWB was specifically retested over 15 days with two SWB assessments separated by a treadmill session (then testing again the potential effect of exercise on SWB) in a group of four rats. This evaluation was done daily, from days 1 to 5, then on days 8 and 15.

Finally, the repeatability of measurements of tactile sensitivity and PEAP (with nociceptive stimulation) was tested in a group of five rats over 25 days. These evaluations were done daily, from days 1 to 15, and repeated on days 18 and 25.

**Influence of acclimatization protocols**

In order to determine the most efficient acclimatization protocol associated with the most repeatable data (previously obtained), the next experiment was conducted in a total of 20 animals (four groups of 5 animals). Briefly, over 2 weeks, different acclimatization protocols were tested and included 8 (days -14, -13, -12, -11, -10, -8, -6, -5, -4, -3, -2, -1, 0).
Mechanical sensitivity was measured by assessing the paw withdrawal threshold (PWT) to an increasing pressure stimulus placed on the dorsal surface of the hind paw using a wedge-shaped probe (1.75 mm² of surface) and a cutoff value set at 250 g. The animals were placed in a sling apparatus (Lomir Biomedical Inc., Notre-Dame-de-Île-Perrot, QC, Canada). The probe was applied once on the dorsal surface at a steadily increasing pressure. The PWT was determined when the animal removed the paw from the apparatus, and the required pressure was recorded. Withdrawal thresholds were measured on the right and left hind paws. The data were expressed as PWT in grams.

**Tactile sensitivity** First, the animal was placed inside an elevated metal grid cage to allow just enough space for the rat to move while being restricted. After the rat exploration session during the first 2 minutes, tactile sensitivity was assessed using an Electronic von Frey Anesthesiometer® (IITC Life Science Inc., Woodland Hills, CA, USA) applied to the plantar surface of the hind paws and by measuring the PWT to von Frey ascending mechanical stimuli. Gradually increasing pressure was applied with a mechanical von Frey polypolypropylene probe (0.7 mm², Rigid Tip®, IITC Life Science Inc., Woodland Hills, CA, USA) fitted to a handheld force transducer. The rigid tip was placed perpendicularly into the mid-plantar surface of the paw. The stimulus was continued until the hind paw was withdrawn or elevated such that the force leveled off. Actions such as vocalization, agitation, jumping, and avoidance were considered indicative of the PWT. Voluntary movements associated with locomotion were not considered to be a withdrawal response. The peak of force in grams was recorded with a cutoff value at 100 g. For each animal, triplicates of each hind paw were taken with a 60-s interval between each stimulus.

**Static weight bearing** The weight distribution through the right and left knee was assessed using an Incapacitance Meter® (IITC Life Science Inc., Woodland Hills, CA, USA) to measure SWB distribution in the two hind limbs. The force exerted by each hind limb was measured and analyzed in grams, but reported in percentage of total body weight (%BW) to normalize the data. Rats were allowed to acclimate to the testing apparatus and were placed in an elevated metal grid cage to allow just enough space for the rat to move while being restricted. After the rat exploration session during the first 2 minutes, tactile sensitivity was assessed using an Electronic von Frey Anesthesiometer® (IITC Life Science Inc., Woodland Hills, CA, USA) applied to the plantar surface of the hind paws and by measuring the PWT to von Frey ascending mechanical stimuli. Gradually increasing pressure was applied with a mechanical von Frey polypolypropylene probe (0.7 mm², Rigid Tip®, IITC Life Science Inc., Woodland Hills, CA, USA) fitted to a handheld force transducer. The rigid tip was placed perpendicularly into the mid-plantar surface of the paw. The stimulus was continued until the hind paw was withdrawn or elevated such that the force leveled off. Actions such as vocalization, agitation, jumping, and avoidance were considered indicative of the PWT. Voluntary movements associated with locomotion were not considered to be a withdrawal response. The peak of force in grams was recorded with a cutoff value at 100 g. For each animal, triplicates of each hind paw were taken with a 60-s interval between each stimulus.

**Operant testing** The PEAP was used as operant testing apparatus [33, 40, 49]. Rats were placed into test cage apparatus that was painted half white and half black. Neither side was illuminated with additional light. With the cage on an elevated metal grid, the observer, located below, determined the preferential location of the rat. The 20-minute observation period began after 2 minutes of acclimatization/exploration to the test environment on each occasion.

**Operant testing without nociceptive stimulation** The percentage of time spent on the black or white side of the test apparatus was calculated from observation of the preferential location every 15 s.

**Operant testing with nociceptive stimulation** If the rat was on the black side of the test apparatus, the preferential location of the right (ipsilateral to possible MIA intrarticular injection) hind paw (RHP) was stimulated with a thin wire (60 g) every 15 s, to prompt withdrawal of the limb. When the rat was on the white side of the cage, a similar mechanical stimulation was applied, but to the plantar surface of the left (contralateral) hind paw (LHP). The percentage of time in the black and white side of the test apparatus was calculated from observation of the preferential location every 15 s. The
calculations were sequenced by successive blocks (n = 4) of 5-minute periods. Moreover, the total number of crossings from the white to the dark side was noted to detect any decrease in activity. If a rat remained in the crossing tunnel, it would be stimulated to advance and complete its crossing.

Rotarod Using a Rotamex 4/8® (Columbus Instruments Inc., Columbus, OH, USA) with a previously published protocol [29], the rats were exposed to an acceleration speed of 5 to 16 rpm, over 60 s, before being maintained at this speed, while the time before falling was monitored with a cutoff time of 3 minutes.

Phase 2: concurrent validity with the MIA model
Experimental design
In the second phase, a pilot study (n = 24 rats) was conducted to test the concurrent validity of different functional and neuropeptide pain assessment methods in the MIA rat OA model. A single intra-articular injection of MIA was performed in the right knee of 16 animals distributed among two groups (n = 8 each). An additional sham group (n = 8) received a single intra-articular injection (50 μL) of 0.9 % NaCl. For the purpose of the study, one of the two MIA groups also received a punctual lidocaine (L) injection (MIA-L group) in the right knee on days 7, 14, and 21. At the end of the 21 days of the experimentation, all animals were euthanized with an overdose of isoflurane and a sacrifice by transection of the cervical spine before spinal cord collection.

Acclimatization period and baseline assessment
The study began with an acclimatization period for the selected optimal outcomes (SWB, tactile sensitivity, PEAP, rotarod, and treadmill), according to the optimal acclimatization protocol of five occurrences (days -14, -7, -5, -3, and -1) obtained in phase 1. Because of pain induction in phase 2, tactile sensitivity could be considered as punctate tactile allodynia evaluation (PTAE). Baseline values were acquired at day -1 in this order of evaluation, following the above-described testing procedures: SWB, PTAE, and PEAP with nociceptive stimulation, rotarod and treadmill, with intra-articular injection of MIA at day 0 in the right knee.

Intra-articular injection
On day 0, fasted (3–6 h) rats from all groups were premedicated with buprenorphine hydrochloride (0.02 mg/kg IM; Buprenex® injectable, Reckitt Benckiser Inc., Mississauga, ON, Canada) and mask-anesthetized with a 2 % isoflurane–O₂ mixture. After surgical preparation, a single intra-articular injection of 2 mg MIA (monosodium iodoacetate, BioUltra®, ≥98 %, Sigma-Aldrich Canada Co., no. I9148-5G, Oakville, ON, Canada) dissolved in isotonic saline, or saline 0.9 % (both 50 μL volume) was administered through the infrapatellar ligament of the right knee, using a 26-gauge, 0.5-inch needle mounted on a 0.5-mL syringe. On days 7, 14, and 21 post-MIA injection, 25 minutes before functional assessment, rats from the MIA-L group were again similarly anesthetized with a single intra-articular injection of lidocaine through the infrapatellar ligament of the right knee. Lidocaine Neat® (2 %, Zoetis Canada, Kirkland, QC, Canada) was injected at a volume of 50 μL using a 26-gauge, 0.5-inch needle mounted on a 0.5-mL syringe.

Post-injection evaluation
The assessments were performed according to the specific schedules of the different groups on days 3, 7, 14, and 21 post injection, and conducted as described for phase 1. For the MIA-L group on days 7, 14, and 21, the evaluation started 25 minutes after the animals recovered from anesthesia. The evaluation sequence was as follows: SWB (%BW), PTAE (grams), PEAP (percentage of time spent on the dark side), rotarod (seconds) and treadmill (TNTC). The schedule of evaluation was designed to obtain the SWB at rest and the PTAE data before the operant testing evaluation, as this test elicits many PWT stimulations.

Proteomic analysis
Reagents and solutions Acetic anhydride 99.5 % (Ac₂O) and ammonium bicarbonate (NH₄HCO₃) were obtained from Sigma-Aldrich Inc. (St Louis, MO, USA). SP and CGRP were purchased from Phoenix Pharmaceuticals Inc. (Belmont, CA, USA). Acetonitrile was purchased from Thermo Fisher Scientific Inc. (NJ, USA), and trifluoroacetic acid, formic acid and ammonium hydroxide 28.0–30.0 % (NH₄OH) were purchased from J.T. Baker® (Phillipsburg, NJ, USA). Standard solutions were prepared as previously performed [54].

Instrumentation The tandem mass spectrometry coupled to high-performance liquid chromatography (HPLC-MS/MS) system comprises a Thermo Surveyor autosampler, a Thermo Surveyor MS pump and a Thermo LCQ Advantage Ion Trap Mass Spectrometer (Thermo Fisher Scientific Inc., San Jose, CA, USA). Data were acquired and analyzed with Xcalibur™ 1.4 (Thermo Fisher Scientific Inc., San Jose, CA, USA), and regression analysis were performed with PRISM® (version 5.0d) (GraphPad Software Inc., La Jolla, CA, USA) using the nonlinear curve fitting module with an estimation of the goodness of fit. The calibration lines were constructed from the peak-area ratios of targeted neuropeptides (SP or CGRP) and the acetylated SP analog internal standard.
Bioanalytical methods Acetylated SP was used as the internal standard. The reaction was performed as previously described [54] and the analytical method used was also based on a previously published method [55]. The internal standard solution was tested by HPLC-MS/MS in multiple reactions monitoring (MRM) mode and no residual SP were detected.

Spinal cord sample preparation At the end of the 21 days of experimentation, the entire spinal cord tissue of rats (n = 24) was rapidly collected by a flush of saline within the lumbar spinal canal following deep anesthesia with isoflurane and sacrifice by transection of the cervical spine. Samples were snap-frozen in liquid nitrogen and stored at −80 °C pending analysis. Each spinal cord was weighed accurately and homogenized using a tissue tear or following the addition of phosphate-buffered saline solution (PBS) 0.01 M at a ratio of 1:5 (v/v) and protease inhibitor cocktail (Sigma-Aldrich Inc., Oakville, ON, Canada, number PP8340) at the same ratio. The samples were sonicated and the homogenate was mixed with acetonitrile at a ratio of 1:1 (v/v) to remove larger proteins. The samples were vortexed and centrifuged for 10 minutes (x12,000 g) and the supernatant was transferred into an injection vial then spiked with the internal standard solution at a ratio of 1:1 (v/v). The spinal cords from a naive group (n = 5) in phase 1 were also collected to obtain a baseline value from normal rats to normalize values obtained from the MIA, MIA-L, and sham groups.

Statistical analysis All statistical analyses were performed two-sided with an alpha value set at 0.05 (phase 1) or 0.10 (phase 2) using a statistical software program (SAS system for Windows, version 9.2, Cary, NC, USA). The alpha value for phase 2 was set at 0.1 because this phase was an exploratory study. In a pilot study, it is acceptable to set a higher alpha value when the study has the hopes of finding an effect that could lead to a promising scientific discovery [56] in order to increase the power (consequently decreasing the risk of type II error), but increasing the chances of type I error (i.e., saying there is a difference when there is not). To be consistent with the statistical rules of correction for multiple comparisons, phase 2 results were presented as adjusted p values (adj-P) because the values obtained in the statistical report need to be multiplied by the total number of comparisons. The normality of the outcomes was verified using the Shapiro-Wilk test and the homogeneity of variance was assessed using the absolute values of the residuals of the mixed model, when appropriate.

Phase 1: reliability of pain assessment methods in normal rats
For mechanical nociceptive thresholds and SWB, the effect of the circadian cycle was assessed using the paired t test adapted for a crossover design. Moreover, the effect of covariates of interest, namely observer, exercise, limb (when both left and right limbs were tested), or trials (when replicates were conducted), was assessed using a general linear model. Generalized linear mixed model analyses for repeated measures were conducted to test the effect of groups on TNTC and rotarod (lognormal distribution), and PEAP (Poisson distribution). Models accounted for baseline measurements using the baseline as covariates. This enabled assessment of the effect of the procedure over time using each subject as its own control. For each model, the best structure of the covariance model was assessed using information criteria that measure the relative fit of competing covariance models. When comparing the 5-minute periods, the Bonferroni adjustment was applied (initial alpha value divided by 4).

Outcome repeatability (test-retest reliability) was assessed by computing the intraclass correlation coefficient (ICC). The ICC is a measure of the proportion of variance that is attributable to objects of measurement. Quantifying the test-retest reliability, the closer the ICC is to 1.0, the higher the reliability and the lower the error variance [57]. A ratio of 0.3–0.4 indicates fair agreement, 0.5–0.6 moderate agreement, 0.7–0.8 strong agreement, and >0.8 almost perfect agreement. Moreover, the coefficient of variation (CV), as a normalized measure of dispersion of the distribution, was used to test the effect of the proposed acclimatization protocols. The CV for each variable was calculated at day -14 (initial assessment), and the variation in CV was assessed at the end of each acclimatization protocol as the CV ratio of day -1 (final assessment) to day -14. At the initial assessment (day -14), the CV interpretation was as follows: <10 % indicated almost perfect dispersion, 11–25 % light dispersion, and 26–40 % fair dispersion. The day -1/ day -14 CV ratio indicated improvement (decrease in variability) related to the acclimatization protocol if it was <1, and deterioration (increase in variability) if >1.

Phase 2: concurrent validity with the MIA model
The SWB and PTAE data were expressed as the average obtained from the three trials on the RHP. Data were then analyzed using linear mixed models (SWB and PTAE) or generalized linear mixed models for repeated measures. Treatment groups and day were considered as fixed effects and animals in groups as random effects. Models accounted for baseline measurement using the baseline as a covariate. For each model, the best structure of the covariance model was assessed using a graphical method (plots of covariance versus lag in time between pairs of observations compared to different
covariance models), and using information criteria that measure the relative fit of competing covariance models. When multiple comparisons were carried out, the Tukey-Kramer adjustment was used to obtain adjusted-P values. Neuropeptide data were analyzed using the unpaired exact Wilcoxon test with an alpha value set at 0.10 following non-parametric Kruskal-Wallis one-way analysis of variance.

Results
Phase 1: reliability of pain assessment methods in normal rats
Data variability and influence of environment
The repeatability of measurements made with different assessment methods was tested in normal rats, and the influence of environment, including observer, inverted circadian cycle (activity during the day), exercise, limb, and trial, was assessed on testing.

Mechanical sensitivity We did not find any effect of observer, circadian cycle, exercise, or limb in the PWT measured with the Randall Selitto test Paw Pressure Meter®. However, the data obtained with this test were highly variable among individuals and not repeatable (ICC <0.3).

Tactile sensitivity The PWT measured with the Electronic von Frey Anesthesiometer® in normal rats gave average values of 40–80 g in both hind limbs. The observer, the circadian cycle, and exercise did not produce any effect on tactile sensitivity. No significant difference between the right and left hind limbs, or trial effect (in the triplicates) was observed. However, the data were markedly variable over the whole period (6 days in total) with an ICC for both hind limbs <0.5. Following repetition of the experiment in five rats over 25 days, the ICC improved after excluding the first 2 weeks of daily evaluation. More precisely, the ICC for days 15, 18, and 25 was >0.8 for both hind limbs (Table 1).

Static weight bearing In normal animals, the Incapacitance Meter® apparatus measured average values of weight distributed over each hind limb between 35 and 38 % BW. The observer, the circadian cycle, and exercise did not produce any effect on SWB. No significant difference between the right and left hind limbs, or trial effect (in the triplicates) was observed. When analyzing the last two days of assessment (in comparison to the whole period of 6 days), the ICC improved (Table 2), and this was particularly evident for the SWB ICC after exercise (ICC >0.7 in both hind limbs for the last 2 days of assessment). This suggests that the treadmill exercise slightly decreased the inter-individual variability in SWB measurement. Finally, following repetition of evaluation over 15 days with in four rats, the ICC improved after excluding the first week of daily evaluation (days 1 to 5), with a value ≥0.66 for days 8 and 15 in both hind limbs (Table 2).

Treadmill The treadmill exercise sessions were generally well accepted by female Sprague-Dawley rats (84 % acceptability). Neither the observer, nor the circadian cycle produced any effect on the TNTC. The TNTC was extremely repeatable with an ICC of 0.84. A period effect was demonstrated ($P = 0.003$) in the 15-day study in four rats (Fig. 1). Post hoc analysis showed that the initial and final 5-minute periods were different for TNTC ($P = 0.0002$), whereas both intermediate 5-minute periods (numbers 2 and 3) were highly repeatable with an ICC of 0.73 and 0.92, respectively.

Place escape/avoidance paradigm The first experiment with operant testing was done without nociceptive stimulus. Neither the observer, nor the circadian cycle produced any effect on the preferential localization. The localization was highly repeatable among animals, with an ICC of 0.90, where the rats spent 91 % of their time on the black side. A period effect was demonstrated ($P < 0.0001$) in the 25-day study of five rats (Fig. 2). The PEAP assessment with nociceptive stimulation once again demonstrated robust repeatability, with an ICC of 0.83, and rats spent 81 % of their time on the black side. The post hoc analysis showed that the intermediate 5-minute periods (numbers 2 and 3) were similar in the percentage of time, and were highly repeatable.

Table 1 Test-retest reliability of the tactile sensitivity evaluation

|                      | LHP | RHP |
|----------------------|-----|-----|
| ICC over the whole period | 0.78 | 0.26 |
| ICC for days 7, 15, 18, and 25 | 0.79 | 0.27 |
| ICC for days 15, 18, and 25 | 0.84 | 0.81 |

A group of normal rats ($n = 5$) was tested with the Electronic von Frey Anesthesiometer® daily from days 1 to 15 and then on days 18 and 25. The intraclass correlation coefficients (ICCs) for values calculated for the entire evaluation period were compared to values calculated after exclusion of the first week and the first two weeks of assessment. LHP left hind paw, RHP right hind paw

Table 2 Test-retest reliability of the static weight bearing

|                      | Before exercise | After exercise |
|----------------------|-----------------|----------------|
|                      | LHP | RHP | LHP | RHP |
| ICC over the whole period | 0.00 | 0.00 | 0.00 | 0.23 |
| ICC for days 8 and 15 | 0.67 | 0.66 | 0.66 | 0.76 |

A group of normal rats ($n = 4$) was tested for static weight bearing before and after treadmill exercise daily from days 1 to 5 and then on days 8 and 15. The intraclass correlation coefficients (ICCs) calculated for the entire evaluation period were compared to ICCs calculated after exclusion of the first week of assessment. LHP left hind paw, RHP right hind paw
and different ($P \leq 0.0216$) from the initial and final 5-minute periods.

**Rotarod** Neither the observer, nor the circadian cycle produced any effect on the performance time in the rotarod, and this performance time was highly repeatable with an ICC of 0.92.

**Influence of acclimatization protocols and comparison of assessment method variability**

When looking at the different assessment methods for the initial day of acclimatization (day -14), inter-individual variability (CV) appeared lower for the SWB, followed by PEAP, tactile sensitivity, and treadmill (TNTC) evaluation, with mechanical sensitivity last (Table 3). The variation in CV at day -1, normalized to day -14, as tested by the day -1/day -14 CV ratio, was compared between acclimatization protocols for the different pain assessment methods (Table 3). The most intensive protocol with the highest number of acclimatization procedures ($n = 8$) presented the lowest variability between days -1 and -14, similar to the protocol with 6 or 5 days of acclimatization. The protocol with only 4 days of acclimatization yielded the highest variations in CV. The acclimatization protocol using five occurrences of exposition to different assessment methods appeared the most appropriate to limit variability in assessment.

**Phase 2: concurrent validity with the MIA model**

The MIA injection successfully induced pain-related changes as assessed by SWB, PTAE, PEAP, and TNTC. However, the rotarod was not sensitive to MIA-induced pain, as all groups had similar (maximal) time of acceptance. In consequence, no further analysis was conducted with this testing modality. The sham injection was not totally neutral when compared to baseline values: while no effect was present for SWB or TNTC, the sham group had a transient decrease in PTAE (days 7 and 14) and PEAP (days 3 and 7). The response to lidocaine injection varied by assessment method: a clear analgesic effect was noted with PTAE (on days 7 and 14), and PEAP (on days 7, 14 and 21); a trend toward better performance was observed with TNTC, but no difference was observed with MIA for SWB. Neuropeptide spinal quantification permitted validation of the lidocaine treatment effect and the pain generated by MIA injection.

**Static weight bearing**

Analysis of SWB data demonstrated a group effect ($P = 0.0005$), a time effect ($P < 0.0001$) and a time x group effect ($P = 0.005$). In the MIA group, the nadir of weight force was observed on day 3 and was different from values recorded on days 7 (adj-$P = 0.005$), 14 (adj-$P = 0.01$) and 21 (adj-$P = 0.001$) (Fig. 3). No significant difference within time was observed for the sham group, whereas in the MIA-L group, day 3 RHP SWB (without lidocaine injection) was lower than on day 14 (adj-$P = 0.001$). Compared to the sham group, the RHP SWB decreased on day 3 in the MIA (adj-$P = 0.002$) and the MIA-L (adj-$P = 0.001$) groups. Subsequently, the RHP SWB in the MIA group returned to levels similar to...
those in the sham group, and at no time point of evaluation did the lidocaine injection provide any benefit.

**Punctate tactile allodynia evaluation**

Descriptive statistics for the RHP PTAE over the evaluation days are provided in Table 4. The PWT was lower after the MIA injection on days 3, 7, 14, and 21. This was also the case for the sham group on days 7 and 14. In the MIA-L group, the nadir in PWT was observed on day 3, whereas a significant increase was observed on days 7 and 14. There was a difference between MIA and MIA-L on days 7 (adj-P = 0.07) and 14 (adj-P = 0.08) (Fig. 4).

**Place escape/avoidance paradigm**

Between-group analysis confirmed a significant treatment effect of lidocaine, in which MIA-L was different from MIA (P = 0.07) and different from sham (P = 0.01) (Fig. 5). The group difference was particularly present for the two intermediate periods 2 and 3 of PEAP assessment previously observed as the most repeatable ones (see “Phase 1”).

**Treadmill**

There was close similarity in the type of performance on the treadmill in the MIA-L and sham groups, in which their TNTC remained comparable to baseline values. Inversely, the TNTC in the MIA group decreased from day 7 onward. However, the observed between-group difference was not significant (P = 0.14).

**Neuropeptides**

The mean relative ratio (RR) of neuropeptide concentrations of SP and CGRP 21 days after induction of OA are shown in Fig. 6. The absolute values of the concentration of neuropeptides have all been normalized to the function of the naive group values and are shown as the RR. Compared to the naive group (Table 5 and Fig. 6) with a RR of 1, the SP concentrations were significantly increased in the MIA model (adj-P = 0.016) with 2 mg of MIA (RR 1.77 ± 0.16) as in the lidocaine treatment group (MIA-L) (RR 1.43 ± 0.09). The level of this peptide was statistically higher in the MIA group (adj-P = 0.029) compared to the sham group injected with saline 0.9 % (RR 1.26 ± 0.14). However, both the sham and MIA-L groups have significantly lower SP concentrations when compared to the MIA group (adj-P = 0.029). The concentration of CGRP was significantly increased in both MIA models (RR 2.29 ± 0.39 and 2.09 ± 0.29 for MIA and MIA-L, respectively). The sham group (RR 1.22 ± 0.07) had an increase too, in comparison with the naive group (adj-P = 0.016). On the other hand, both MIA groups had a statistically significantly higher level of CGRP than the sham group (adj-P = 0.029). When compared to the MIA group, the MIA-L group had a statistically similar level of CGRP neuropeptide (adj-P = 0.200).

---

### Table 3 Coefficient of variation (CV) for each outcome and variation in CV between four protocols of acclimatization

| Functional evaluation | 8 Days | 6 Days | 5 Days | 4 Days |
|-----------------------|--------|--------|--------|--------|
|                       | CV (D-14) | CV* ratio | CV (D-14) | CV* ratio | CV (D-14) | CV* ratio | CV (D-14) | CV* ratio |
| SWB                   | 17.3    | 0.72    | 31.2    | 0.30    | 11.7     | 0.62     | 12.2     | 0.67     |
| PEAP                  | 23.8    | 1.01    | 24.1    | 1.07    | 21.3     | 0.97     | 22.8     | 1.11     |
| TS                    | 42.9    | 0.85    | 22.9    | 1.24    | 20.4     | 1.01     | 27.4     | 1.80     |
| TNTC                  | 36.9    | 1.10    | 106.5   | 0.54    | 31.2     | 0.91     | 38.0     | 1.92     |
| MS                    | 63.3    | 0.74    | 71.8    | 1.07    | 72.2     | 0.71     | 75.3     | 0.53     |

*The functional evaluation includes the values recorded for the right hind limb, when available (static weight bearing (SWB), tactile sensitivity (TS), mechanical sensitivity (MS)), or the response of the animal (place escape/avoidance paradigm (PEAP) and treadmill number of total crossings (TNTC)). *The CV values calculated on day -1 were normalized to the CV values on day -14 (D-14) to test the influence of the acclimatization protocol on the outcome measures. A day -1/day -14 CV ratio value <1 was indicative of improvement in variability and is presented in bold italics.

---

**Fig. 3** Static weight-bearing (SWB) evolution after induction of osteoarthritis (least squares mean ± standard error of the mean). On day 3, the monosodium iodoacetate (MIA) intra-articular injection in the right knee induced asymmetrical weight distribution in the rats injected with MIA (adjusted P value (adj-P) = 0.0024) and rats injected with MIA and punctual lidocaine (MIA-L) (adj-P = 0.0011) compared to rats injected with 0.9 % saline (sham). Subsequently, a statistically significant difference in right hind paw SWB was only observed between the sham and MIA-L groups at days 7 and 21. %BW percentage of body weight. a,b Significant inter-group statistical differences.
Discussion

Rat models are common in OA research as they are easy to customize and are cost-effective [58]. The MIA model in particular can be standardized and is associated with rapidly developing well-characterized lesions [23, 30]. In an effort to improve the translation of preclinical OA research to the clinical field, we conducted a two-phase study, first, to determine the most reliable pain assessment method protocol, and second, to validate this protocol in the most common chemical model of OA in rats with concomitant changes in spinal neuropeptide concentrations.

Initially, the effect of the environment (inverted circadian cycle, activity level (treadmill exercise), and observer) was tested using well-known pain assessment tools. Prior studies have demonstrated an effect of the inverted circadian cycle on pain research protocols with rodents [59–61]. Our results did not suggest any impact of conducting the evaluation during daytime (more convenient for the investigator). Our group reported a significant reduction in variability of kinetics measures after exercise in cats [62] and dogs [63] with OA. The current study confirmed beneficial effects of exercise to reduce SWB (or other outcome) variability in the MIA rat model of OA. This study also qualified TNTC as a quantitative pain measure using spontaneous behavior. Importantly, the study tested reliability and validity of TNTC, and the potential impact on results obtained with other pain assessment methods, which may be used concurrently. Our results confirmed that a broad range of methods can be combined for pain assessment in the same animals while maintaining reliability and scientific validity.

Finally, as different observers can introduce some degree of bias in pain assessment outcomes, inter-rater reliability was tested by observers with different levels of expertise (one intermediate and one advanced). The methodology included in the current study was accessible to an observer with intermediate experience, as no significant difference was identified during analysis based on the level of experience. As a limitation, the number of observers was minimal, as both observers were women, and only objective assessment methods were selected for this study (limiting any bias related to subjective observation). Therefore, such a hypothesis (the potential influence of experience, and/or gender) would need to be tested further before making inferences from the results. This is particularly important, as recent work has established the influence of the observer’s gender in inducing stress-related analgesia in rodents [64]. Similarly, for limiting the influence of interferential factors in studying the effect of environment, only female rats were used. A possible gender effect would need to be tested in future experiments. Indeed, male rodents are recognized as more sensitive to olfactory exposure to males, including men, causing stress and related analgesia [64]. Moreover, sexual dimorphism [65] and hormonal influence [66, 67] have been observed in endogenous pain modulation mechanisms. Finally, women are more represented in the field of chronic pain [68]; however, many reasons have been explored to investigate this finding [69].

Table 4 Mean and standard deviation of the punctate tactile allodynia evaluation by experimental group over time

| Experimental group | Days | Mean | SD  | Mean | SD  | Mean | SD  | Mean | SD  | Mean | SD  |
|-------------------|------|------|-----|------|-----|------|-----|------|-----|------|-----|
|                   | -1   | 53.8 | 11.2| 39.2 | 13.1| 43.1 | 13.7| 40.0 | 10.0| 39.8 | 8.5 |
| MIA-L             | 21   | 70.4 | 16.8| 35.0 | 13.8| 52.6 | 12.7| 47.8 | 14.3| 36.2 | 17.8|
| Sham              | 56.3 | 16.9| 49.0| 14.8| 39.2 | 16.6| 37.0 | 17.6| 45.6 | 17.0|

Descriptive statistics of the punctate tactile allodynia evaluation (PTAE) of the right hind paw. The measure was obtained for the three groups (eight animals per group) in grams on days 3, 7, 14, and 21 following the intra-articular injection of monosodium iodoacetate (MIA). Intra-articular injection was performed on day 0 (2 mg of MIA for the MIA and rats injected with monosodium iodoacetate and punctual lidocaine (MIA-L) groups and 0.9 % NaCl for the sham group). The MIA-L group also received an intra-articular injection of lidocaine in the right knee on days 7, 14, and 21, at 25 minutes before the PTAE. SD standard deviation

![Fig. 4](image_url)

**Fig. 4** Right hind paw (RHP) withdrawal threshold evolution after induction of osteoarthritis (least squares mean ± standard error of the mean). On days 7 (adjusted *P* value (adj-)*P* = 0.07) and 14 (adj-*P* = 0.08), the RHP paw withdrawal threshold was increased for the rats injected with monosodium iodoacetate and punctual lidocaine (MIA-L) when compared with rats injected with MIA.
in preclinical research. This situation can definitely lead to a certain bias [70]. All these previous studies justify our decision to use female rats.

As a recognized indicator of test-retest reliability [57], the ICC demonstrated that assessment of mechanical sensitivity using the Randall Selitto test presents poor repeatability, and this outcome cannot be recommended for a valid reflexive measure of pain. The phase 1 experiments demonstrated that SWB and tactile sensitivity can produce more repeatable data when animals (and the observer) are allowed to acclimate to the test device for at least one week. Similarly, there was a slight reduction in the variability of SWB when measured after treadmill exercise. However, the beneficial effects of exercise were not as significant in the chemically induced OA rat model as those observed in cats with naturally

![Fig. 5](image1.png)

**Fig. 5** Place escape/avoidance paradigm (PEAP) evolution after osteoarthritis induction (least squares mean ± standard error of the mean). The percentage of time spent on the PEAP dark side was statistically higher in the lidocaine-treated rats with monosodium iodoacetate (MIA-L) when compared to the rats injected with monosodium iodoacetate (MIA) (P = 0.07) and the sham group (P = 0.01) group. Data presented here were collected for the whole period of assessment (20 minutes) at each day, but the observed between-group differences were the most obvious during the intermediate periods 2 (5–10 minutes) and 3 (10–15 minutes).

![Fig. 6](image2.png)

**Fig. 6** Spinal substance P (SP) and calcitonin gene-related peptide (CGRP) concentrations 21 days after monosodium iodoacetate (MIA) injection (relative ratio (RR) mean and SD). Mean RR spinal cord concentration was normalized to the naive group. An RR of 1 indicated the concentration of normal rats from the naive group. The RR for SP and CGRP were increased in all groups (including the sham group) but had a higher peak after MIA injection. Lidocaine treatment (L) induced a lesser liberation of SP and CGRP (albeit not statistically significant for the latter) in the spinal cord of the MIA-L group. *a,b,c* Significant inter-group statistical differences (adjusted P value <0.10).
SPMIA-L rats injected with monosodium iodoacetate 10 minutes, and substance P, 15 minutes, respectively) demonstrated the highest calcitonin CGRP value). *Inter-group statistically significant difference (adjusted P value).

### Table 5 Neuropeptides inter-group comparisons in the monosodium iodoacetate osteoarthritis rat model

| Inter-group comparisons | SP   | CGRP |
|-------------------------|------|------|
| Three groups vs. naive rats | 0.016* | 0.016* |
| MIA vs. sham            | 0.029* | 0.029* |
| MIA-L vs. sham          | 0.057* | 0.029* |
| MIA-L vs. MIA           | 0.029* | 0.200 |

*MIA monosodium iodoacetate, MIA-L rats injected with monosodium iodoacetate and treated with punctual lidocaine injection, SP substance P, CGRP calcitonin gene related-peptide. *Inter-group statistically significant difference (adjusted P value)

occurring OA [62, 71]. The PEAP, rotarod, and treadmill activity measured as TNTC appeared to be highly repeatable without requiring prolonged acclimatization. It must be noted that in both treadmill and PEAP, the intermediate periods 2 and 3 (i.e., 5–10 minutes, and 10–15 minutes, respectively) demonstrated the highest repeatability. These results also suggest that the treadmill and PEAP sessions are a little too long, so for future experimentation the session could be reduced in both cases to 15 minutes instead of 20 minutes. To our knowledge, this study is the first to evaluate the test-retest (repeatability) and inter-rater (reproducibility) reliability of a complete set of pain assessment methods in normal rodents.

As a measure of distribution dispersion that does not require similar units and therefore allows comparison of different variables, the CV of each pain assessment method was verified. At the first evaluation, we again observed the poor metrological property of mechanical sensitivity, presenting the highest inter-individual variability (around 70 % CV). Moreover, the different acclimatization protocols did not help to decrease this variability as the variation in CV from the last to the first evaluation was between 0.53 and 1.07. On the other side, our results support the importance of choosing the optimal acclimatization protocol for pain assessment in the rat model. To our knowledge, this study represents the first systematic evaluation of the effect on data variability of different acclimatization protocols, including four to eight assessments over a 2-week period, with a series of tests near or far from the others. The most reliable acclimatization protocol included five assessments with exposure to the testing methods every other day for the last week (days -14, -7, -5, -3, and -1), with baseline values acquired at day -1.

The second exploratory phase of our project evaluated the validity of the most promising pain assessment methods as determined during phase 1, when applied to the MIA model of OA in rats. Briefly, SWB, PTAE, PEAP, and TNTC detected pain-related changes following OA induction with an intra-articular MIA injection and were validated by increased release of spinal neuropeptides such as SP and CGRP. However, the rotarod assessment, as used in our experimental conditions, was not sensitive to induction of OA pain. Moreover, the PTAE and PEAP methods demonstrated that the sham injection of 0.9 % NaCl was not totally neutral, which was confirmed by the augmentation of spinal liberation of SP (26 times higher) and CGRP (22 times higher) in the sham group. Interestingly, PTAE and PEAP also confirmed the analgesic effect of intra-articular lidocaine injection by the downregulation of spinal neuropeptides, whereas TNTC and SWB did not detect the expected analgesic effect. These results suggest that SWB detects more biomechanical alterations of the joint than ongoing pain and consequently, could be a sensitive method to detect knee joint dysfunction.

The enhanced escape/avoidance behavior and lower PWT were previously demonstrated in both neuropathic and inflammatory pain models [33, 41, 47, 72, 73]. The higher sensitivity of PEAP compared to PTAE in detecting the efficacy of pain relief was also demonstrated in other studies [33].

It would be logical to consider that animals would allocate roughly a similar amount of time in both environments if they do not show natural preference or aversion to one of the two environments in the PEAP testing. This study clearly establishes a strong preference of the rat, a nocturnal animal, to the dark side of the test apparatus. The acclimatization of rats to the test apparatus is fast, the establishment of a baseline is preferable, and both intermediate periods 2 and 3 are highly repeatable. Moreover, PEAP assessment includes both classical (Pavlovian) and operant conditioning in the process of training [42]. When compared with PEAP, PTAE required a longer acclimatization period for both the animal and the observer (at least one week as demonstrated in this study). However, assessing the escape/avoidance behavior using the PEAP required a much longer evaluation time (with 20 to 30 minutes required for each animal), being too labor-intensive to the experimenters, while no automated apparatus is commercially available for this test.

Interestingly, the intra-articular lidocaine injection affected both PTAE and PEAP, and to a lesser degree TNTC, but did not alter changes in weight bearing on...
the RHP. The lack of effect of lidocaine on SWB could be related to reduced pain in the absence of movement in this model. In a recent study [25], intra-articular lidocaine (200 μL) was efficient to reduce the shift in weight bearing at day 14 post-MIA injection, but only for the highest dose of MIA (4.8 mg). The lower MIA dose and volume in our study (2 mg and 50 μL) combined with the lower sensitivity of SWB may be responsible for the lack of effect with this method, while PEAP and PTAE accurately captured the expected pharmacological effects of lidocaine. Intra-articular lidocaine was chosen for the analgesic test in this study, because of the apparently controversial results obtained in conditioning procedures with non-steroidal anti-inflammatory and opioid drugs (for review, see [42]).

These findings may be useful when designing studies of the efficacy of analgesia using the MIA-induced OA rat model. Moreover, there is also some evidence that the combination of the quick-acting effect of lidocaine (reaching a peak effect at 10 minutes after the intra-articular injection on a CatWalk) [74] and the necessary time to induce a change in the distribution of gait in supraspinal locomotor areas in patients with OA [75], seems to explain the lack of detection of lidocaine analgesia by SWB. Previous studies combined with our results, provide evidence for future use of a continuous infusion of lidocaine to obtain a more sustained analgesic effect, attaining higher lidocaine synovial levels for a prolonged time period.

The intra-articular injection of saline (sham group) generated some hyperalgesia or allodynia, as assessed by PTAE and reflected by the observed change in the operant testing. This is supported by the recent finding of some increased NF-kB activity on days 3 and 7 measured by in vivo luminescent imaging in a transgenic mouse model receiving an intra-articular injection of saline [76]. Moreover, in the MIA mouse model tested in the same study, temporal kinetics of NF-kB activity were strongly correlated with mechanical allodynia (PTAE) and serum interleukin (IL)-6 levels in the inflammatory phase (day 3) of this model, while serum IL-1β was strongly correlated with pain sensitivity in the chronic pain phase (up to day 28) [76]. An increase in the intra-articular pressure and possible injection-related inflammation are proposed to explain this finding. Based on these results, a neutral control group (without intra-articular injection) may be valuable in future experiments.

The MIA model is recognized as valuable in OA research for its ability to detect analgesic effects of different drugs and compounds. The initial inflammatory phase of this model allows the evaluation of various non-steroidal anti-inflammatory drugs and cyclo-oxygenase inhibitors [14, 24, 27, 77]. Moreover, the efficacy of morphine, gabapentin, pregabalin, and the transient receptor potential vanilloid receptor antagonist was successfully demonstrated in this model [15–17, 24, 77]. Moreover, some studies showed that MIA-induced OA leads to an increase in the neuron firing rate and a reduced activation threshold of the afferent nerve fibers [78], which consequently leads to sensitization of spinal neurons in the dorsal horn [79]. In this study, spinal cord neuropeptide quantification suggests and supports development of central sensitization in this model. Indeed, our study confirms an increase in spinal biomarkers of SP and CGRP, as previously observed in the MIA model [51].

The upregulation of spinal neuropeptides observed in this study suggests activation of the peptidergic afferent C-fibers, resulting in central sensitization. It has been well-demonstrated [80], by relative increasing expression of target gene mRNA like pro-inflammatory cytokines (IL-1 and tumor necrosis factor) and pain mediators (CGRP, SP, neuropeptide Y, and galanin), that MIA-induced joint degeneration in rats generates an animal model suitable for mechanistic and pharmacologic studies on nociceptive pain pathways caused by OA. Altogether, this provides further key in vivo evidence that OA pain could be caused by central sensitization through communication between peripheral OA nociceptors and the central sensory system [81, 82]. Despite the fact that SWB did not detect lidocaine treatment on day 21, or asymmetry of weight distribution, our study clearly demonstrated that lidocaine analgesic effects noted by PEAP were translated by concomitant significant down-regulation of spinal SP, which was 34 times lower, and of CGRP, which was 20 times lower on day 21.

These results mimic similar therapeutic effects on behavior and SP and CGRP spinal cord expression of intra-articular resiniferatoxin [83] and proteasome inhibitor MG132 [84] in the MIA OA pain model in rats. Unfortunately, we observed that the MIA model caused temporary changes of short duration (return to baseline values at day 21 post injection) and relies on a disease mechanism (chemical inhibition of glyceraldehyde-3-phosphate dehydrogenase activity in chondrocytes, resulting in cell death following the disruption of its cellular glycolysis process [15, 16, 18]) that differs from human natural OA, which could limit the predictability of the therapeutic effect of analgesic and disease-modifying agents. Finally, higher levels of spinal neuropeptides at sacrifice clearly confirms that our model caused some long-term pain or OA damage.

Conclusion
Pain assessment methods used with the MIA model should be selected and scheduled appropriately. In this study only mechanical sensitivity had poor metrological properties, but SWB, the operant PEAP testing, tactile sensitivity, rotarod, and treadmill (TNTC) were repeatable
under different environmental conditions. The rotarod test did not achieve sufficient sensitivity to detect OA pain induced by MIA injection in rats and may not be included in future studies. For detecting the analgesic effect of local administration of lidocaine, the pain assessment method that demonstrated the best results was the operant testing, which had the greatest sensitivity, followed by PTAE, whereas SWB had some limitation in sensitivity. Spinal neuropeptide quantification at the end of the experiment has allowed us to validate the effect of positive lidocaine treatment in a more objective manner, as MIA can induce pain. However, the main limitation of this study was the small sample size. Furthermore, it was possible to increase the validity and reliability of pain assessment methods with an optimal acclimatization protocol (five assessments over 2 weeks). In addition, the sham intra-articular saline injection was not totally neutral, particularly with more sensitive methods such as PEAP, PTAE, and this was confirmed by the release of spinal neuropeptides. We therefore recommend the addition of a naive control group (without intra-articular injection). Moreover, increased neuropeptide levels obviously support the central sensitization observed in the MIA rat model. The present results highlight potential for these neuromediators as pharmacological biomarkers for analgesic testing in association with sensitive functional assessment methods.

Abbreviations

Adj-P, adjusted p value; BW, body weight; CGRP, calcitonin gene-related peptide; CV, coefficient of variation; D, day; HPLC-MS/MS, tandem mass spectrometry coupled to high-performance liquid chromatography; ICC, intraclass correlation coefficient; IL, interleukin; L, lidocaine; LHP, left hind paw; LS-Mean, least square means; MIA, monosodium iodoacetate; MM, multiple reactions monitoring; MS, mechanical sensitivity; n, number of animals; OA, osteoarthritis; P, probability; PEAP, place escape/avoidance paradigm; PTAE, punctate tactile allodynia evaluation; PWT, paw withdrawal threshold; RHP, right hind paw; RPM, revolutions per minute; RR, relative ratio; SD, standard deviation; SEM, standard error of the mean; SP, substance P; SWB, static weight bearing; TNTC, treadmill number of total crossings; TS, tactile sensitivity; V/V, volume/volume

Acknowledgements

The authors would like to address special thanks to Mrs Virginia Wallis for editing the manuscript. The authors would like to thank ArthroLab Inc. and CiToxLAB North-America Inc. personnel for their contributions to this work.

Funding

This study was partly supported by a Discovery grant (#327158-2008; #441651-2013; Eric Troncy) and a Collaborative Research and Development grant (#413899-2011 with ArthroLab Inc.; Eric Troncy) from the Natural Sciences and Engineering Research Council of Canada (NSERC), supporting pain bio-analyses, by an ongoing New Opportunities Fund grant (#4983) and a Leader Opportunity Fund grant (#24601; Eric Troncy) from the Canada Foundation for Innovation, supporting pain equipment, and ArthroLab, Inc. and CiToxLAB North America, Inc. for their collaboration, access to animals, personnel and related facilities. This study was funded by a Pfizer Neuropathic Pain Research award (#WS368118; Eric Troncy) from Pfizer Canada, Inc.

Availability of data and materials

The datasets supporting the conclusions of the article are available in the Papyrus repository (www.bib.umontreal.ca/theses).

Authors’ contributions

Each co-author has taken an active part in this project from the conception and design of the content (CO, JG, SA, JMP, JPP, and ET), to the technical manipulations (CO, JG, JAG, DG, CP, SA, MAD, PS, FB, and ET), analysis, and interpretation of published data (CO, JG, MG, FB, and ET), and drafting and revising of the article (all co-authors) with the final approval of the submitted version. Each of them completely agrees with the presented data, and believes that the manuscript represents honest work.

Authors’ information

This manuscript is part of the PhD thesis of CO. Several authors are recognized experts in the field of animal pain assessment (ET and FB), laboratory animal pain assessment (ET, PS, and SA), rheumatology (JMP, JPP, and ET) and others are their graduate students (CO, XS, MG, JAG, DG, CP, and MAD).

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

During the study, care and use of animals were subject to and approved by the Comité d’Éthique de l’Utilisation des Animaux of Université de Montréal (#Rech-1495) and conducted in accordance with principles outlined in the current Guide to the Care and Use of Experimental Animals published by the Canadian Council on Animal Care and the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health.

Author details

1 Groupe de Recherche en Pharmacologie Animale du Québec (GREPAQ), Department of Biomedical Sciences, Faculty of veterinary medicine, Université de Montréal, 1500 des Vétérinaires Street, P.O. Box 5000, St-Hyacinthe, Quebec J2S 7C6, Canada. *Osteoarthritis Research Unit, Research Center Hospital of Montreal University (CRCHUM), Montreal, Quebec, Canada. 2 Department of Physiology and Biophysics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada. 3 CiToxLAB North America Inc., Laval, Quebec, Canada.

Received: 6 May 2016 Accepted: 9 June 2016

Published online: 23 June 2016

References

1. Little CB, Hunter DJ. Post-traumatic osteoarthritis: from mouse models to clinical trials. Nat Rev Rheumatol. 2013;9:485–97.
2. Lawrence RC, Felson DT, Helmig CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:28–35.
3. Hootman JM, Helmig CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54:226–9.
4. Kissin I. The development of new analgesics over the past 50 years: a taste of real breakthrough drugs. Anesth Analg. 2010;110:780–9.
5. Palmer AM, Sundstrom L. Translational medicines research. Drug Discov Today. 2013;18:505–5.
6. Dolgin E. Animalgesic effects. Nat Med. 2010;16:1237–40.
7. Mao J. Translational pain research: achievements and challenges. J Pain. 2009;10:283–94.
8. Mogil JS. Animal models of pain: progress and challenges. Nat Rev Neurosci. 2009;10:283–94.
9. Yezierski RP, Vierck CJ. Should the hot-plate test be reincarnated? J Pain. 2011;12:936–7. author reply 938-939.
10. Blackburn-Munro G. Pain-like behaviours in animals - how human are they? Trends Pharmacol Sci. 2004;25:299–305.
11. Vierck CJ, Hanson PT, Yezierski RP. Clinical and pre-clinical pain assessment: are we measuring the same thing? Pain. 2008;135:7–10.
12. Mogil JS, Crager SE. What should we be measuring in behavioral studies of chronic pain in animals? Pain. 2004;112:125-2.
13. Moreau M, Pelletier JP, Lussier B, D’Anjou MA, Blond L, Pelletier JM, et al. A posteriori comparison of natural and surgical destabilization models of canine osteoarthritis. Biomed Res Int. 2013;2013:180453.
14. Bove SE, Calcaterra SL, Brooker RM, Huber CM, Guzman RE, Juneau PL, et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage. 2003;11:821–30.
15. Combe R, Bramwell S, Field MJ. The monosodium iodoacetate model of osteoarthritis: a model of chronic nociceptive pain in rats? Neurosci Lett. 2004;370:236–40.

16. Fernslough J, Gentry C, Malcanigo M, Fox A, Rediske J, Pellias T, et al. Pain related behaviour in two models of osteoarthritis in the rat knee. Pain. 2004;112:89–93.

17. Ferreira-Gomes J, Adesia S, Sousa RM, Mendonca M, Castro-Lopez JM. Dose-dependent expression of neuronal injury markers during experimental osteoarthritis induced by monosodium iodoacetate in the rat. Mol Pain. 2012;8:50.

18. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillot P. Monoiodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphometry, and biochemistry. Arthritis Rheum. 1997;40:1670–9.

19. Guzman RE, Evans MG, Bove S, Moreno B, Kligore K. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol. 2003;31:169–24.

20. Kelly S, Dunham JP, Murray F, Read S, Donaldson LF, Lawson SN. Spontaneous firing in C-fibers and increased mechanical sensitivity in A-fibers of knee joint-associated mechanoreceptive primary afferent neurons during MIA-induced osteoarthritis in the rat. Osteoarthritis Cartilage. 2012;20:305–13.

21. Kobayashi K, Imaizumi R, Sumichika H, Tanaka H, Goda M, Fukunari A, et al. Sodium iodoacetate-induced experimental osteoarthritis and associated pain model in rats. J Vet Med Sci. 2003;65:1195–9.

22. Liu P, Okun A, Ren J, Guo RC, Ospovit MH, Xie J, et al. Ongoing pain in the MIA model of osteoarthritis. Neurosci Lett. 2011;493:72–5.

23. Marker CL, Pomonis JD. The monosodium iodoacetate model of osteoarthritis pain in the rat. Methods Mol Biol. 2012;851:239–48.

24. Nagase H, Kamakura S, Shimada K. Establishment of a novel objective and quantitative method to assess pain-related behavior in monosodium iodoacetate-induced osteoarthritis in rat knee. J Pharmacol Toxicol Methods. 2012;66:29–36.

25. Okun A, Liu P, Davis P, Ren J, Remienik B, Brion T, et al. Afferent drive elicits ongoing pain in a model of advanced osteoarthritis. Pain. 2012;153:924–33.

26. Orita S, Ishikawa T, Miyagi M, Ochi H, Inoue G, Eguchi Y, et al. Pain-related sensory innervation in monoiodoacetate-induced osteoarthritis in rat knees that gradually develops neuronal injury in addition to inflammatory pain. BMC Musculoskelet Disord. 2011;12:134.

27. Pomonis JD, Boulet JM, Gottshall SL, Phillips S, Sellers R, Bunton T, et al. Development and pharmacological characterisation of a rat model of osteoarthritis pain. Pain. 2005;114:339–46.

28. Thakur M, Rahman W, Hobbs C, Dickenson AH, Bennett DL. Characterisation of a peripheral neuropathic component of the rat monosodium iodoacetate model of osteoarthritis. Pain Neurosci. 2012;17:e3730.

29. Vonsy JL, Ghandehari J, Dickenson AH. Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats. Eur J Pain. 2009;13:786–93.

30. Lapopoulou-Adamidou K, Lelovas P, Karadimas EV, Liakou C, Triantafillopoulos IK, Dontas I, et al. Useful animal models for the research of osteoarthritis. Eur J Orthop Surg Traumatol. 2014;24:263–71.

31. Barrot M. Tests and models of nociception and pain in rodents. Neuroscience. 2012;211:139–50.

32. Edwards RR, Sarlani E, Wessellman U, Billig RB. Quantitative assessment of experimental pain perception: multiple domains of clinical relevance. Pain. 2005;114:315–9.

33. Boyce-Rustay JM, Zhong C, Kohnken R, Baker SJ, Simler GH, Wensink EJ, et al. Comparison of mechanical allodynia and the affective component of inflammatory pain in rats. Neuropsychopharmacology. 2010;35:583–47.

34. Vierck CJ Jr, Kline RH, Wiley RG. Intrathecal substance p-saporin attenuates operant escape from nociceptive thermal stimuli. Neuroscience. 2003;119:223–32.

35. King CD, Devine DP, Vierck CJ, Rodgers J, Yezienski RP. Differential effects of stress on escape and reflex responses to nociceptive thermal stimuli in the rat. Brain Res. 2003;987:214–22.

36. Maudeli AP, Acosta-Rua A, Vierck C. An operant assay of thermal pain in conscious, unrestrained rats. J Neurosci Methods. 2000;97:19–29.

37. Pedersen LH, Blackburn-Munro G. Pharmacological characterisation of pain escape/avoidance behaviour in the rat chronic constriction injury model of neuropathic pain. Psychopharmacology (Berl). 2006;185:208–17.

38. Vierck CJ, Acosta-Rua A, Nelligan R, Tester N, Maudelii A. Low dose systemic morphine attenuates operant escape but facilitates innate reflex responses to thermal stimulation. J Pain. 2002;3:309–19.

39. Zhang XJ, Zhang TW, Hu SJ, Xu H. Behavioral assessments of the aversive quality of pain in animals. Neurosci Bull. 2011;27:61–7.

40. Woolf CJ. Windup and central sensitisation are not equivalent. Pain. 1996;66:105–8.

41. Ferland CE, Paillieux F, Vachon P, Beaudry F. Determination of specific neuropeptides modulation time course in a rat model of osteoarthritis pain by liquid chromatography ion trap mass spectrometry. Neuropeptides. 2011;45:423–9.

42. Galá L, Pozza M, Zanni M, Manzini CU, Manzini E, Hofkert T. Peptide plasticity in primary sensory neurons and spinal cord during adjuvant-induced arthritis in the rat: an immunocytochemical and in situ hybridization study. Neuroscience. 1998;82:575–89.

43. Levine JD, Coller DH, Babauim Al, Moskowitz MA, Helms CA. Hypothesis: the nervous system may contribute to the pathophysiology of rheumatoid arthritis. J Rheumatol. 1985;12:406–11.

44. Beaudry F, Ferland CE, Vachon P. Identification, characterization and quantification of specific neuropeptides in rat spinal cord by liquid chromatography electrospray quadrupole ion trap mass spectrometry. Biomed Chromatogr. 2009;23:940–50.

45. Che FY, Fricker LD. Quantitation of neuropeptides in Cpe(fat)/Cpe(fat) mice using differential isotopic tags and mass spectrometry. Anal Chem. 2002;74:3190–8.

46. Cunran-Everett DB, Benos DJ. Guidelines for reporting statistics in journals published by the American Physiological Society. Am J Physiol Regul Integr Comp Physiol. 2004;287:R247–249.

47. Weir JP. Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM. J Strength Cond Res. 2005;19:231–40.

48. Gregory MH, Capito N, Kukodi K, Stoker AM, Cook JL, Sherrman SL. A review of translational animal models for knee osteoarthritis. Arthritis. 2012;2012:764621.

49. Jansen van’t Land C, Hendriksen CF. Change in locomotor activity pattern in mice afflicted by osteoarthritis. Res Vet Sci. 2013;95:219–28.
64. Sorge RE, Martin LJ, Isbester KA, Sotocinal SG, Rosen S, Tuttle AH, et al. Olfactory exposure to males, including men, causes stress and related analgesia in rodents. Nat Methods. 2014;11:629–32.

65. Gaumond I, Spooner MF, Marchand S. Sex differences in opioid-mediated pain inhibitory mechanisms during the interphase in the formalin test. Neuroscience. 2007;146:666–74.

66. Coulombe MA, Spooner MF, Gaumond I, Carrier JC, Marchand S. Estrogen receptors beta and alpha have specific pro- and anti-nociceptive actions. Neuroscience. 2011;184:172–82.

67. Liu X, Li W, Dai L, Zhang T, Xia W, Liu H, et al. Early repeated administration of progesterone improves the recovery of neuropathic pain and modulates spinal 18 kDa-translocator protein (TSPO) expression. J Steroid Biochem Mol Biol. 2014;143:130–40.

68. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley 3rd JL. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain. 2009;10:447–85.

69. Mogil JS. Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon. Nat Rev Neurosci. 2012;13:859–66.

70. Mogil JS, Chanda ML. The case for the inclusion of female subjects in basic science studies of pain. Pain. 2005;117:1–5.

71. Guillot M, Moreau M, Heit M, Martel-Pelletier J, Pelletier JP, Troncy E. Characterization of osteoarthritis in cats and meloxicam efficacy using objective chronic pain evaluation tools. Vet J. 2013;196:360–7.

72. Baatrup C, Jensen TS, Finnerup NB. Pregabalin attenuates place escape/avoidance behavior in a rat model of spinal cord injury. Brain Res. 2011;1370:129–35.

73. LaGraize SC, Labuda CJ, Rutledge MA, Jackson RL, Fuchs PN. Differential effect of anterior cingulate cortex lesion on mechanical hypersensitivity and escape/avoidance behavior in an animal model of neuropathic pain. Exp Neurol. 2004;188:139–48.

74. Ferreira-Gomes J, Adaes S, Mendonca M, Castro-Lopes JM. Analgesic effects of lidocaine, morphine and diclofenac on movement-induced nociception, as assessed by the Knee-Bend and CatWalk tests in a rat model of osteoarthritis. Pharmacol Biochem Behav. 2012;101:617–24.

75. Jahn K, Deutschlander A, Stephan T, Kalla R, Hufner K, Wagner J, et al. Supraspinal locomotor control in quadrupeds and humans. Prog Brain Res. 2008;171:353–62.

76. Bowles RD, Mata BA, Bell RD, Mwangi TK, Huebner JL, Kraus VB, et al. In Vivo luminescence imaging of NF-kappaB activity and serum cytokine levels predict pain sensitivities in a rodent model of osteoarthritis. Arthritis Rheum. 2014;66:637–46.

77. Ivanavicius SP, Ball AD, Heapy CG, Westwood FR, Murray F, Read SJ. Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation. Pain. 2007;128:272–82.

78. Schuelert N, McDougall JJ. Electrophysiological evidence that the vasoactive intestinal peptide receptor antagonist VIP6-28 reduces nociception in an animal model of osteoarthritis. Osteoarthritis Cartilage. 2006;14:1155–62.

79. Harvey VL, Dickenson AH. Behavioural and electrophysiological characterisation of experimentally induced osteoarthritis and neuropathy in C57Bl/6 mice. Mol Pain. 2009;5:18.

80. Irm HJ, Kim JS, Li X, Kotwal N, Sumner DR, van Wijnen AJ, et al. Alteration of sensory neurons and spinal response to an experimental osteoarthritic pain model. Arthritis Rheum. 2010;62:2995–3005.

81. Zhang RX, Ren K, Dubner R. Osteoarthritis pain mechanisms: basic studies in animal models. Osteoarthritis Cartilage. 2013;21:1308–15.

82. Alain M, Sagar DR, Stockley EG, Spencer CH, Prior M, Chapman V, et al. Neural correlates of hyperalgesia in the monosodium iodoacetate model of osteoarthritis pain. Mol Pain. 2016;12:1–12.

83. Kim Y, Kim EH, Lee KS, Lee K, Park SH, Na SH, et al. The effects of intra-articular resiniferatoxin on monosodium iodoacetate-induced osteoarthritic pain in rats. Korean J Physiol Pharmacol. 2016;20:129–36.

84. Ahmed AS, Li J, Erlendsson-Harris H, Stark A, Bakkin G, Ahmed M. Suppression of pain and joint destruction by inhibition of the proteasome system in experimental osteoarthritis. Pain. 2012;153:18–26.